[
  {
    "ts": null,
    "headline": "Guidance Watch: 2 Companies Bullishly Raising Forecasts",
    "summary": "One company remains at the forefront of the AI frenzy, whereas the other has seen insiders dive in post-earnings.",
    "url": "https://finnhub.io/api/news?id=94f7c684ae0386b429439f42637cc1795fe0eeecdeae8b655560614a60508bb0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755206400,
      "headline": "Guidance Watch: 2 Companies Bullishly Raising Forecasts",
      "id": 136367939,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "One company remains at the forefront of the AI frenzy, whereas the other has seen insiders dive in post-earnings.",
      "url": "https://finnhub.io/api/news?id=94f7c684ae0386b429439f42637cc1795fe0eeecdeae8b655560614a60508bb0"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Rise Late Afternoon",
    "summary": "Health care stocks advanced late Thursday afternoon, with the NYSE Health Care Index gaining 0.7% an",
    "url": "https://finnhub.io/api/news?id=4fa2bfd8f0c073808f895e65ab3d75ca3071e52139116e2c9557bc0ffad0ada2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755201281,
      "headline": "Sector Update: Health Care Stocks Rise Late Afternoon",
      "id": 136367940,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks advanced late Thursday afternoon, with the NYSE Health Care Index gaining 0.7% an",
      "url": "https://finnhub.io/api/news?id=4fa2bfd8f0c073808f895e65ab3d75ca3071e52139116e2c9557bc0ffad0ada2"
    }
  },
  {
    "ts": null,
    "headline": "Oracle, Eli Lilly, Terawulf: Trending Tickers",
    "summary": "Oracle (ORCL) stock is in focus on reports that the company will cut jobs in its cloud division — part of a broader push to cut costs. Eli Lilly (LLY) stock is rising on the company's $1.3 billion collaboration with Superluminal Medicines to develop artificial intelligence (AI)–powered treatments for obesity. Bitcoin (BTC-USD) miner TeraWulf's (WULF) stock is jumping on the announcement that Alphabet (GOOG, GOOGL) will take an 8% stake in the company. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=5a9f2cf2f80a01c6d03fc5fbce51bd496facc3550289261d56fb0a7837a2ff4d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755201255,
      "headline": "Oracle, Eli Lilly, Terawulf: Trending Tickers",
      "id": 136367941,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Oracle (ORCL) stock is in focus on reports that the company will cut jobs in its cloud division — part of a broader push to cut costs. Eli Lilly (LLY) stock is rising on the company's $1.3 billion collaboration with Superluminal Medicines to develop artificial intelligence (AI)–powered treatments for obesity. Bitcoin (BTC-USD) miner TeraWulf's (WULF) stock is jumping on the announcement that Alphabet (GOOG, GOOGL) will take an 8% stake in the company. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=5a9f2cf2f80a01c6d03fc5fbce51bd496facc3550289261d56fb0a7837a2ff4d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Says It Will Raise European Prices of its Medicines as Trump Pushes for U.S. Price Cuts",
    "summary": "The White House’s effort to lower drug prices in the U.S. is bringing higher drug prices to Europe.  The Indiana-based drugmaker  Eli Lilly  said on Thursday that it is raising the list prices of its drugs overseas.  Lilly said that “the prices for medicines paid by governments and health systems need to increase in other developed markets like Europe in order to make them lower in the US.”",
    "url": "https://finnhub.io/api/news?id=c440d63583157647477e96be7ce6e97554893e1f7b47a570a8c142c796cbd39b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755195960,
      "headline": "Eli Lilly Says It Will Raise European Prices of its Medicines as Trump Pushes for U.S. Price Cuts",
      "id": 136367942,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The White House’s effort to lower drug prices in the U.S. is bringing higher drug prices to Europe.  The Indiana-based drugmaker  Eli Lilly  said on Thursday that it is raising the list prices of its drugs overseas.  Lilly said that “the prices for medicines paid by governments and health systems need to increase in other developed markets like Europe in order to make them lower in the US.”",
      "url": "https://finnhub.io/api/news?id=c440d63583157647477e96be7ce6e97554893e1f7b47a570a8c142c796cbd39b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to Raise U.K. Price of Mounjaro for Out-of-Pocket Patients",
    "summary": "Pharma giant  Eli Lilly  said it is negotiating to raise drug prices in Europe, starting in the U.K. with the weight-loss drug Mounjaro, so that it can comply with the Trump administration’s goal of bringing down prices in the U.S.  Lilly said Thursday that it has an agreement with the U.K. government to raise the list price of Mounjaro for patients who pay for it out-of-pocket.  Lilly will more than double the list price of Mounjaro’s highest dose from about $165 to about $446.",
    "url": "https://finnhub.io/api/news?id=2b892dcbfae49e6a71683eb5fd320c9c0d7b68dbe58c542e0da602c338d10200",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755195600,
      "headline": "Eli Lilly to Raise U.K. Price of Mounjaro for Out-of-Pocket Patients",
      "id": 136367943,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pharma giant  Eli Lilly  said it is negotiating to raise drug prices in Europe, starting in the U.K. with the weight-loss drug Mounjaro, so that it can comply with the Trump administration’s goal of bringing down prices in the U.S.  Lilly said Thursday that it has an agreement with the U.K. government to raise the list price of Mounjaro for patients who pay for it out-of-pocket.  Lilly will more than double the list price of Mounjaro’s highest dose from about $165 to about $446.",
      "url": "https://finnhub.io/api/news?id=2b892dcbfae49e6a71683eb5fd320c9c0d7b68dbe58c542e0da602c338d10200"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY): “Wall Street Was Really Wrong,” Says Jim Cramer",
    "summary": "We recently published 10 Stocks On Jim Cramer’s Radar Including Big Tech Firms. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company (NYSE:LLY) hasn’t been doing well on the stock market lately. The shares have lost 21% over the past month, primarily on the back of […]",
    "url": "https://finnhub.io/api/news?id=31ed6b088835dd7dfbc800f0d8a3887d203d036a8e842b250def2f18d344872f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755193445,
      "headline": "Eli Lilly and Company (LLY): “Wall Street Was Really Wrong,” Says Jim Cramer",
      "id": 136367944,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks On Jim Cramer’s Radar Including Big Tech Firms. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company (NYSE:LLY) hasn’t been doing well on the stock market lately. The shares have lost 21% over the past month, primarily on the back of […]",
      "url": "https://finnhub.io/api/news?id=31ed6b088835dd7dfbc800f0d8a3887d203d036a8e842b250def2f18d344872f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Advances Cardiometabolic Therapeutics In US$1.3 Billion Collaboration With Superluminal",
    "summary": "Eli Lilly (LLY) recently collaborated with Superluminal Medicines to advance therapeutics targeting cardiometabolic diseases, potentially offering significant financial opportunities. Despite this promising partnership and generally strong earnings reports, Eli Lilly observed a 10% decline in its share price in the last quarter amidst broader market volatility, including inflation concerns affecting interest rate expectations. While the market on a whole exhibited an upward trend, evidenced...",
    "url": "https://finnhub.io/api/news?id=6ef1e8157947c6142ee267ac9bc81eff15690bfb223c2998e77f3791c10b207f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755192717,
      "headline": "Eli Lilly (LLY) Advances Cardiometabolic Therapeutics In US$1.3 Billion Collaboration With Superluminal",
      "id": 136367945,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) recently collaborated with Superluminal Medicines to advance therapeutics targeting cardiometabolic diseases, potentially offering significant financial opportunities. Despite this promising partnership and generally strong earnings reports, Eli Lilly observed a 10% decline in its share price in the last quarter amidst broader market volatility, including inflation concerns affecting interest rate expectations. While the market on a whole exhibited an upward trend, evidenced...",
      "url": "https://finnhub.io/api/news?id=6ef1e8157947c6142ee267ac9bc81eff15690bfb223c2998e77f3791c10b207f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly seeks more GPCR weight loss drugs in $1.3bn research deal",
    "summary": "The deal follows a similar billion-dollar GPCR partnership made by rival Novo Nordisk earlier this year.",
    "url": "https://finnhub.io/api/news?id=6be409d808593855a62aa526f1f08f7ab85db1770fbbcab1cbc6015d186e6d40",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755192712,
      "headline": "Eli Lilly seeks more GPCR weight loss drugs in $1.3bn research deal",
      "id": 136367946,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The deal follows a similar billion-dollar GPCR partnership made by rival Novo Nordisk earlier this year.",
      "url": "https://finnhub.io/api/news?id=6be409d808593855a62aa526f1f08f7ab85db1770fbbcab1cbc6015d186e6d40"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Up as Eli Lilly Rises -- Health Care Roundup",
    "summary": "Health Care Up as Eli Lilly Rises -- Health Care Roundup",
    "url": "https://finnhub.io/api/news?id=1b7f7da377c72baa38c1fcf6e6f25c662a546d53091daac82ae201da29ad1602",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755192420,
      "headline": "Health Care Up as Eli Lilly Rises -- Health Care Roundup",
      "id": 136384874,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Health Care Up as Eli Lilly Rises -- Health Care Roundup",
      "url": "https://finnhub.io/api/news?id=1b7f7da377c72baa38c1fcf6e6f25c662a546d53091daac82ae201da29ad1602"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Hikes UK Mounjaro Price  By Up To 170% As Trump Pressure Mounts",
    "summary": "Eli Lilly said Thursday it will hike the UK list price of its diabetes and weight-loss drug Mounjaro by up to 170%.",
    "url": "https://finnhub.io/api/news?id=d63d265ab4e62da47c9aab329004e067774c347544cc0d0d5c519c68fc076b1d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755191196,
      "headline": "Eli Lilly Hikes UK Mounjaro Price  By Up To 170% As Trump Pressure Mounts",
      "id": 136349212,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly said Thursday it will hike the UK list price of its diabetes and weight-loss drug Mounjaro by up to 170%.",
      "url": "https://finnhub.io/api/news?id=d63d265ab4e62da47c9aab329004e067774c347544cc0d0d5c519c68fc076b1d"
    }
  },
  {
    "ts": null,
    "headline": "C3.ai downgrade, Oracle–Alphabet deal, Eli Lilly & Superluminal",
    "summary": "Yahoo Finance anchor Julie Hyman tracks Thursday's top stocks and market movers in this Market Minute. C3.ai (AI) stock dips after Oppenheimer downgraded the stock to Perform from Outperform, citing weak preliminary first quarter results. Oracle's (ORCL) and Alphabet's (GOOG, GOOGL) cloud computing units are partnering to bring Gemini's artificial intelligence (AI) models to Oracle's applications. Eli Lilly (LLY) is partnering with Superluminal Medicines to develop new weight-loss drugs using AI. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=b03ef5784531d74a546a4306f60ed8d6c3952febb0912d26ef7c17ad1e37193b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755188468,
      "headline": "C3.ai downgrade, Oracle–Alphabet deal, Eli Lilly & Superluminal",
      "id": 136349145,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Yahoo Finance anchor Julie Hyman tracks Thursday's top stocks and market movers in this Market Minute. C3.ai (AI) stock dips after Oppenheimer downgraded the stock to Perform from Outperform, citing weak preliminary first quarter results. Oracle's (ORCL) and Alphabet's (GOOG, GOOGL) cloud computing units are partnering to bring Gemini's artificial intelligence (AI) models to Oracle's applications. Eli Lilly (LLY) is partnering with Superluminal Medicines to develop new weight-loss drugs using AI. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=b03ef5784531d74a546a4306f60ed8d6c3952febb0912d26ef7c17ad1e37193b"
    }
  },
  {
    "ts": null,
    "headline": "Top Stock Movers Now: Tapestry, Deere, Eli Lilly, and More",
    "summary": "U.S. equities were lower at midday as wholesale inflation rose more than expected in July.",
    "url": "https://finnhub.io/api/news?id=708c3bc4274cc63cce432ea522cf7b54f82a7375107751074fe45c5cde557f0c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755186367,
      "headline": "Top Stock Movers Now: Tapestry, Deere, Eli Lilly, and More",
      "id": 136349214,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "U.S. equities were lower at midday as wholesale inflation rose more than expected in July.",
      "url": "https://finnhub.io/api/news?id=708c3bc4274cc63cce432ea522cf7b54f82a7375107751074fe45c5cde557f0c"
    }
  },
  {
    "ts": null,
    "headline": "Lanier Law Firm Representing Health Choice Alliance in Litigation Alleging Eli Lilly Offered Kickbacks to Texas Health Care Providers",
    "summary": "MARSHALL, Texas, August 14, 2025--Texas Attorney General Ken Paxton has filed a lawsuit in state court against Eli Lilly and Co., accusing the pharmaceutical giant of bribing and inducing medical providers to prescribe its most profitable drugs. In return, physicians were offered unlawful payments and a range of free services in violation of state law.",
    "url": "https://finnhub.io/api/news?id=ec1dcdd9efc2fef42ff270dfaf608c9c5904073c2cc6a03f97f609ee44dbf88d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755184980,
      "headline": "Lanier Law Firm Representing Health Choice Alliance in Litigation Alleging Eli Lilly Offered Kickbacks to Texas Health Care Providers",
      "id": 136349215,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "MARSHALL, Texas, August 14, 2025--Texas Attorney General Ken Paxton has filed a lawsuit in state court against Eli Lilly and Co., accusing the pharmaceutical giant of bribing and inducing medical providers to prescribe its most profitable drugs. In return, physicians were offered unlawful payments and a range of free services in violation of state law.",
      "url": "https://finnhub.io/api/news?id=ec1dcdd9efc2fef42ff270dfaf608c9c5904073c2cc6a03f97f609ee44dbf88d"
    }
  },
  {
    "ts": null,
    "headline": "Lilly says it will raise drug prices in Europe, responding to Trump threats",
    "summary": "As the Trump administration works to implement a “most-favored nation” policy, Lilly said it’s “rebalancing” drug prices to “align” costs across different countries.",
    "url": "https://finnhub.io/api/news?id=e91620c5e0fbb4faad2677a544b7a0c132c5b3b809e9d18379d4d051f8223d08",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755184560,
      "headline": "Lilly says it will raise drug prices in Europe, responding to Trump threats",
      "id": 136367947,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As the Trump administration works to implement a “most-favored nation” policy, Lilly said it’s “rebalancing” drug prices to “align” costs across different countries.",
      "url": "https://finnhub.io/api/news?id=e91620c5e0fbb4faad2677a544b7a0c132c5b3b809e9d18379d4d051f8223d08"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Raises UK Obesity Shot Price as Trump Pressures Pharma",
    "summary": "The current list price in the UK for Lilly’s Mounjaro ranges from £92 ($124.89) to £122 a month, depending on the dose.  This will increase to between £133 and £330 from Sept. 1, with the US drugmaker saying it aims to bring rates in line with other countries.",
    "url": "https://finnhub.io/api/news?id=1533298dbba2ef2db17700d9e82cf667821d396c8b8b55ddba479d65435df68d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755184055,
      "headline": "Lilly Raises UK Obesity Shot Price as Trump Pressures Pharma",
      "id": 136349216,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The current list price in the UK for Lilly’s Mounjaro ranges from £92 ($124.89) to £122 a month, depending on the dose.  This will increase to between £133 and £330 from Sept. 1, with the US drugmaker saying it aims to bring rates in line with other countries.",
      "url": "https://finnhub.io/api/news?id=1533298dbba2ef2db17700d9e82cf667821d396c8b8b55ddba479d65435df68d"
    }
  },
  {
    "ts": null,
    "headline": "Goodpath Adds Self-Pay GLP-1 Option Through Integration with LillyDirect Pharmacy Provider GiftHealth",
    "summary": "Goodpath, the leading virtual provider of whole-person care for chronic conditions, today announced a pharmacy integration agreement with Gifthealth, Eli Lilly and Company's LillyDirect pharmacy provider. LillyDirect is Lilly's direct-to-consumer digital healthcare platform. This integration will help eligible Goodpath members, if prescribed Zepbound® (tirzepatide) by their provider, have more seamless access to effective medicine.",
    "url": "https://finnhub.io/api/news?id=0a00411d017faac7d3cc3970b005d3a2ea76b3d25dd280fd0806ad9b1a6f1c1a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755176400,
      "headline": "Goodpath Adds Self-Pay GLP-1 Option Through Integration with LillyDirect Pharmacy Provider GiftHealth",
      "id": 136349217,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Goodpath, the leading virtual provider of whole-person care for chronic conditions, today announced a pharmacy integration agreement with Gifthealth, Eli Lilly and Company's LillyDirect pharmacy provider. LillyDirect is Lilly's direct-to-consumer digital healthcare platform. This integration will help eligible Goodpath members, if prescribed Zepbound® (tirzepatide) by their provider, have more seamless access to effective medicine.",
      "url": "https://finnhub.io/api/news?id=0a00411d017faac7d3cc3970b005d3a2ea76b3d25dd280fd0806ad9b1a6f1c1a"
    }
  },
  {
    "ts": null,
    "headline": "Zacks Investment Ideas feature highlights: IonQ, Hims and Hers, Eli Lilly and TransMedics",
    "summary": "Insider moves in IonQ, Hims and Hers, Eli Lilly, and TransMedics reveal bold buys, record sales, and signals worth watching.",
    "url": "https://finnhub.io/api/news?id=c021bb40d44826418a19bf8c0a920bbed6860531d74a6da408b2df71f10d8e09",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755174900,
      "headline": "Zacks Investment Ideas feature highlights: IonQ, Hims and Hers, Eli Lilly and TransMedics",
      "id": 136349218,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Insider moves in IonQ, Hims and Hers, Eli Lilly, and TransMedics reveal bold buys, record sales, and signals worth watching.",
      "url": "https://finnhub.io/api/news?id=c021bb40d44826418a19bf8c0a920bbed6860531d74a6da408b2df71f10d8e09"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly raises UK price of weight-loss drug Mounjaro by up to 170%",
    "summary": "Eli Lilly has raised the UK price of its popular weight-loss drug Mounjaro by as much as 170 per cent, as it tries to address complaints by Donald...",
    "url": "https://finnhub.io/api/news?id=658935415468bd26ceeaeca842ae94a778a876658d8641858840fbc4ec1c089c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755174721,
      "headline": "Eli Lilly raises UK price of weight-loss drug Mounjaro by up to 170%",
      "id": 136349219,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly has raised the UK price of its popular weight-loss drug Mounjaro by as much as 170 per cent, as it tries to address complaints by Donald...",
      "url": "https://finnhub.io/api/news?id=658935415468bd26ceeaeca842ae94a778a876658d8641858840fbc4ec1c089c"
    }
  },
  {
    "ts": null,
    "headline": "Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI",
    "summary": "Lilly currently dominates the obesity treatment market, which is estimated to be worth $150 billion by the next decade, and is trying to strengthen its foothold in the space through the development of next-generation drugs, acquisitions and partnerships.  The deal gives Lilly access to Superluminal's proprietary artificial-intelligence-driven platform to rapidly discover potential drug candidates targeting G-protein-coupled receptors (GPCR) - a class of proteins that can influence a range of physiological processes including metabolism, cell growth and immune responses - the drug developer said on Thursday.",
    "url": "https://finnhub.io/api/news?id=b9402cc667e537adad8a34998e0315a7084f812244e6e37dd9b34cd34966f64a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755173759,
      "headline": "Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI",
      "id": 136349220,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly currently dominates the obesity treatment market, which is estimated to be worth $150 billion by the next decade, and is trying to strengthen its foothold in the space through the development of next-generation drugs, acquisitions and partnerships.  The deal gives Lilly access to Superluminal's proprietary artificial-intelligence-driven platform to rapidly discover potential drug candidates targeting G-protein-coupled receptors (GPCR) - a class of proteins that can influence a range of physiological processes including metabolism, cell growth and immune responses - the drug developer said on Thursday.",
      "url": "https://finnhub.io/api/news?id=b9402cc667e537adad8a34998e0315a7084f812244e6e37dd9b34cd34966f64a"
    }
  },
  {
    "ts": null,
    "headline": "Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity",
    "summary": "Superluminal Medicines, a drug discovery company integrating AI/ML, protein dynamics, and structural biology to rapidly unlock the most challenging G protein-coupled receptors (GPCRs), today announced a collaboration with Eli Lilly and Company (\"Lilly\") to advance small molecule therapeutics targeting undisclosed GPCR targets relevant to cardiometabolic diseases and obesity. The collaboration will leverage Superluminal's cutting-edge, structure-based drug discovery platform, combined with Lilly'",
    "url": "https://finnhub.io/api/news?id=8702c8b02679c3e5aa4147f4f5c7a81e5a46f6a0ee4223d6902fc049c4f0c029",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755173040,
      "headline": "Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity",
      "id": 136349221,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Superluminal Medicines, a drug discovery company integrating AI/ML, protein dynamics, and structural biology to rapidly unlock the most challenging G protein-coupled receptors (GPCRs), today announced a collaboration with Eli Lilly and Company (\"Lilly\") to advance small molecule therapeutics targeting undisclosed GPCR targets relevant to cardiometabolic diseases and obesity. The collaboration will leverage Superluminal's cutting-edge, structure-based drug discovery platform, combined with Lilly'",
      "url": "https://finnhub.io/api/news?id=8702c8b02679c3e5aa4147f4f5c7a81e5a46f6a0ee4223d6902fc049c4f0c029"
    }
  },
  {
    "ts": null,
    "headline": "UK prices for weight loss jab jump as drugmaker bows to Trump demands",
    "summary": "The US drugmaker Eli Lilly has bowed to demands from Donald Trump by raising the prices of its weight-loss jab for UK customers.",
    "url": "https://finnhub.io/api/news?id=9bd3d85089362877eec8ab23e4a8a1bf14f4f7f19c1015ac9177c7f17bc78f2e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755168891,
      "headline": "UK prices for weight loss jab jump as drugmaker bows to Trump demands",
      "id": 136344738,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The US drugmaker Eli Lilly has bowed to demands from Donald Trump by raising the prices of its weight-loss jab for UK customers.",
      "url": "https://finnhub.io/api/news?id=9bd3d85089362877eec8ab23e4a8a1bf14f4f7f19c1015ac9177c7f17bc78f2e"
    }
  },
  {
    "ts": null,
    "headline": "It's Time To Be All-In On Novo Nordisk",
    "summary": "Novo Nordisk's current valuation is highly attractive, offering a compelling risk-reward for turnaround investors despite recent stock declines and margin...",
    "url": "https://finnhub.io/api/news?id=b7a3a79c4522f20c81abf0ac5abb8a4426da50ef09a4716692cbe39dbd8a473e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755168658,
      "headline": "It's Time To Be All-In On Novo Nordisk",
      "id": 136348250,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153927815/image_2153927815.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk's current valuation is highly attractive, offering a compelling risk-reward for turnaround investors despite recent stock declines and margin...",
      "url": "https://finnhub.io/api/news?id=b7a3a79c4522f20c81abf0ac5abb8a4426da50ef09a4716692cbe39dbd8a473e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's (NYSE:LLY) Earnings Are Of Questionable Quality",
    "summary": "NYSE:LLY 1 Year Share Price vs Fair Value Explore Eli Lilly's Fair Values from the Community and select yours Last...",
    "url": "https://finnhub.io/api/news?id=805c0659e75d6403a00772b4ee0aecd824453c7ee42e38fa34304ab82c4666d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755167817,
      "headline": "Eli Lilly's (NYSE:LLY) Earnings Are Of Questionable Quality",
      "id": 136344739,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NYSE:LLY 1 Year Share Price vs Fair Value Explore Eli Lilly's Fair Values from the Community and select yours Last...",
      "url": "https://finnhub.io/api/news?id=805c0659e75d6403a00772b4ee0aecd824453c7ee42e38fa34304ab82c4666d6"
    }
  },
  {
    "ts": null,
    "headline": "4 trends among retail investors according to Robinhood's CIO",
    "summary": "Institutional investors are feeling more bullish, but where does overall retail investor sentiment sit? Robinhood's (HOOD) chief investment officer, Stephanie Guild, joins Market Domination to share some of the key trends she's noticed among retail traders, including Nvidia (NVDA) and Tesla (TSLA) being the most common stocks traded by bears and bulls alike. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=fe09502ad734d963c3f8f362a02a0ccd2b48fd1245af874ffae567c4503dd162",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755167430,
      "headline": "4 trends among retail investors according to Robinhood's CIO",
      "id": 136344587,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Institutional investors are feeling more bullish, but where does overall retail investor sentiment sit? Robinhood's (HOOD) chief investment officer, Stephanie Guild, joins Market Domination to share some of the key trends she's noticed among retail traders, including Nvidia (NVDA) and Tesla (TSLA) being the most common stocks traded by bears and bulls alike. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=fe09502ad734d963c3f8f362a02a0ccd2b48fd1245af874ffae567c4503dd162"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma Has a New Vision for Selling Drugs. It’s Going to the Mattresses.",
    "summary": "Amid pressure from the White House, U.S. drug companies are experimenting with direct-to-consumer sales models that cut out the middlemen.",
    "url": "https://finnhub.io/api/news?id=7ede2251f91bf9e2d54ddb933553fa689bf92972b927da2349a5650f3035911e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755156600,
      "headline": "Big Pharma Has a New Vision for Selling Drugs. It’s Going to the Mattresses.",
      "id": 136344742,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Amid pressure from the White House, U.S. drug companies are experimenting with direct-to-consumer sales models that cut out the middlemen.",
      "url": "https://finnhub.io/api/news?id=7ede2251f91bf9e2d54ddb933553fa689bf92972b927da2349a5650f3035911e"
    }
  },
  {
    "ts": null,
    "headline": "Vanguard Health Care Fund's Strategic Moves: Johnson & Johnson Takes Center Stage with 2. ...",
    "summary": "Exploring the Latest Investment Strategies of Vanguard Health Care Fund (Trades, Portfolio)",
    "url": "https://finnhub.io/api/news?id=b7f9cf22f31edc7d93fcd1269f279c632c858a297945b49aeb233d5e71b8de51",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755151256,
      "headline": "Vanguard Health Care Fund's Strategic Moves: Johnson & Johnson Takes Center Stage with 2. ...",
      "id": 136344743,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Exploring the Latest Investment Strategies of Vanguard Health Care Fund (Trades, Portfolio)",
      "url": "https://finnhub.io/api/news?id=b7f9cf22f31edc7d93fcd1269f279c632c858a297945b49aeb233d5e71b8de51"
    }
  },
  {
    "ts": null,
    "headline": "5 Must-Read Analyst Questions From Eli Lilly’s Q2 Earnings Call",
    "summary": "Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit expectations, yet the market response was notably negative. Management attributed the year-on-year growth to ongoing strength from key products such as Mounjaro and Zepbound, with robust demand in both diabetes and obesity markets. CEO David A. Ricks highlighted the positive clinical data from the ATTAIN-1 orforglipron trial and strong uptake of new products, but acknowledged h",
    "url": "https://finnhub.io/api/news?id=4c3f845cf9a3ced0f3ffe5c26f6f5362d74118f8e248675f50849eb3e6001840",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755149764,
      "headline": "5 Must-Read Analyst Questions From Eli Lilly’s Q2 Earnings Call",
      "id": 136344745,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit expectations, yet the market response was notably negative. Management attributed the year-on-year growth to ongoing strength from key products such as Mounjaro and Zepbound, with robust demand in both diabetes and obesity markets. CEO David A. Ricks highlighted the positive clinical data from the ATTAIN-1 orforglipron trial and strong uptake of new products, but acknowledged h",
      "url": "https://finnhub.io/api/news?id=4c3f845cf9a3ced0f3ffe5c26f6f5362d74118f8e248675f50849eb3e6001840"
    }
  }
]